This is a non-core endpoint: only basic statistics are computed.
Benign neoplasm: Middle ear, nasal cavity and accessory sinuses (controls excluding all cancers)
CD2_BENIGN_EAR_NASAL_SINUS_EXALLC
No definition available.
Endpoint definition
↥
FinnGen phenotype data
individuals
Apply sex-specific rule None
Check conditions None
Check pre-conditions, main-only, mode, registry filters
Hospital Discharge: ICD-10
D14.0&
Hospital discharge: ICD-9
2120
Hospital discharge: ICD-8
2120
Cause of death: ICD-10
D14.0&
Cause of death: ICD-9
2120
Cause of death: ICD-8
2120
2 out of 7 registries used, show all original rules.
-
Check minimum number of events None
-
Include endpoints None
-
Remove individuals based on genotype QC
1144
CD2_BENIGN_EAR_NASAL_SINUS_EXALLC
Control definitions
Control exclude
C3_CANCER
Extra metadata
Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
D14
Name in latin
Neoplasma benignum auris mediae
No upset plot: script not run.
No upset table: script not run.
Similar endpoints
↥List of similar endpoints to
Benign neoplasm: Middle ear, nasal cavity and accessory sinuses (controls excluding all cancers)
based on the number of shared cases.
Broader endpoints:
- Benign neoplasm: Middle ear, nasal cavity and accessory sinuses
- Benign neoplasm of middle ear and respiratory system
- Benign neoplasm of middle ear and respiratory system (controls excluding all cancers)
- Benign neoplasms
- Benign neoplasms (controls excluding all cancers)
Narrower endpoints:
Summary Statistics
↥Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 1144 | 546 | 598 |
| Unadjusted prevalence (%) | 0.28 | 0.24 | 0.33 |
| Mean age at first event (years) | 54.50 | 52.51 | 56.31 |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: CD2_BENIGN_EAR_NASAL_SINUS_EXALLC – Benign neoplasm: Middle ear, nasal cavity and accessory sinuses (controls excluding all cancers)
GWS hits:
Survival analyses between endpoints
↥Not a core endpoint, no data to show.
Drugs most likely to be purchased after Benign neoplasm: Middle ear, nasal cavity and accessory sinuses (controls excluding all cancers)
↥Endpoint not on priority list, no data to show.